Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19173198 | INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVID | April 2025 | February 2026 | Abandon | 10 | 1 | 0 | Yes | No |
| 18602255 | GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOF | March 2024 | July 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18600947 | EGG WHITE PROTEIN ANTI-INFLAMMATORY PEPTIDE AND APPLICATION THEREOF | March 2024 | October 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18581115 | STAPLED ANTIMICROBIAL PEPTIDE | February 2024 | November 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18540219 | GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE | December 2023 | November 2024 | Allow | 11 | 1 | 2 | Yes | No |
| 18512512 | AMYLIN RECEPTOR AGONISTS | November 2023 | August 2024 | Allow | 9 | 0 | 1 | No | No |
| 18492058 | INSECT NEUROPEPTIDES 4 | October 2023 | March 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18492006 | INSECT NEUROPEPTIDES 3 | October 2023 | September 2024 | Allow | 11 | 1 | 1 | No | No |
| 18375639 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | October 2023 | December 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18468535 | MODIFIED PLASMA CLOTTING FACTOR VIII AND METHOD OF USE THEREOF | September 2023 | January 2026 | Allow | 29 | 1 | 1 | Yes | No |
| 18303093 | CARDIAC-SPECIFIC TARGETING-PEPTIDE (CTP), COMPOSITIONS, AND USES THEREOF | April 2023 | February 2026 | Allow | 34 | 2 | 0 | Yes | No |
| 18003572 | HUMAN IL23 RECEPTOR BINDING POLYPEPTIDES | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18079099 | REGULATORY T CELL EPITOPES | December 2022 | September 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17881605 | ULTRASOUND-ASSISTED SIMULATED DIGESTION METHOD OF CASEIN ACTIVE PEPTIDE AND APPLICATION THERE OF IN HEALTH FOODS | August 2022 | November 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17792591 | TARGETING PAR1 AND PAR2 TO REGULATE LIPID AND CHOLESTEROL ABUNDANCE | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17863319 | PHARMACEUTICAL COMPOSITION | July 2022 | February 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17824256 | TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS | May 2022 | June 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17778759 | BIOTIN MOIETY-CONJUGATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING THE SAME | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17742640 | COMPOUNDS AND METHODS FOR INHIBITING PROTOZOAN PARASITES | May 2022 | May 2025 | Allow | 36 | 2 | 0 | No | No |
| 17692471 | COMPOSITIONS COMPRISING PEPTIDES COMPRISING VARIANT KINESIN LIGHT CHAIN 1 AND CELL-PENETRATING PEPTIDES | March 2022 | October 2024 | Allow | 31 | 1 | 0 | No | No |
| 17574947 | METHODS AND COMPOSITIONS FOR NONINVASIVE DETECTION OF ORGAN TRANSPLANT REJECTION | January 2022 | December 2025 | Allow | 47 | 5 | 1 | Yes | No |
| 17562014 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | December 2021 | September 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17557343 | BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE | December 2021 | May 2025 | Abandon | 41 | 3 | 0 | No | No |
| 17551701 | POLYPEPTIDES AND USES THEREOF | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | Yes | No |
| 17526203 | STABILIZED AFGF COMPOSITIONS | November 2021 | September 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17525354 | HEPARIN-BINDING CATIONIC PEPTIDE SELF-ASSEMBLING PEPTIDE AMPHIPHILES USEFUL AGAINST DRUG-RESISTANT BACTERIA | November 2021 | February 2025 | Allow | 39 | 1 | 1 | No | No |
| 17521366 | METHODS FOR TREATING SYMPTOMS OF DRY EYE DISEASE | November 2021 | March 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17593512 | A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | September 2021 | January 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17438646 | SINGLE CHAIN FACTOR VIII MOLECULE | September 2021 | November 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17431867 | PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17430365 | POLYPEPTIDES FOR RESTORING ENDOTHELIAL FUNCTION AND METHODS OF USE THEREOF | August 2021 | April 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17305713 | Isolation and Semi-Synthesis of Rufomycin Analogs | July 2021 | October 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17364153 | HYDROGEL-FORMING PEPTIDES, AND METHODS OF USE THEREOF | June 2021 | March 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17312484 | NOVEL PROTEIN, AND THERAPEUTIC AND COSMETIC USES THEREOF | June 2021 | September 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17334427 | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE | May 2021 | November 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17303200 | COMPOSITION OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREFORE | May 2021 | August 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17286851 | Modified Netrin-1 Peptides and Compositions for Cardioprotection | April 2021 | February 2026 | Abandon | 57 | 5 | 1 | No | No |
| 17230602 | METHOD FOR PREVENTION OR TREATMENT OF OBESITY, REDUCING BODY WEIGHT AND/OR FOOD INTAKE, OR INDUCING SATIETY IN A SUBJECT | April 2021 | February 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17284351 | GLP-1 RECEPTOR ANTAGONISTS | April 2021 | March 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17222636 | CHIMERIC CLOTTING FACTORS | April 2021 | February 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17217285 | MODIFIED PLASMA CLOTTING FACTOR VIII AND METHOD OF USE THEREOF | March 2021 | August 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17214189 | REGULATORY T CELL EPITOPES | March 2021 | June 2024 | Abandon | 39 | 2 | 1 | Yes | No |
| 17209367 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | March 2021 | November 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17203623 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | March 2021 | November 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17259904 | INJECTABLE MICRONIZED HUMAN INSULIN | January 2021 | January 2024 | Abandon | 36 | 4 | 0 | No | No |
| 17135877 | NOVEL LINKER, PREPARATION METHOD, AND APPLICATION THEREOF | December 2020 | January 2026 | Abandon | 60 | 2 | 1 | Yes | Yes |
| 17103386 | Composition and Methods of Controllable Co-Coupling Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics | November 2020 | June 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17056340 | Microneedle Adhesive Patch Based on Hydrogel Formulation | November 2020 | December 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 17067749 | SYNERGISTIC COMBINATION OF CHEMOTHERAPY AND PEPTIDE FOR TREATING CANCER | October 2020 | December 2023 | Abandon | 38 | 0 | 1 | No | No |
| 17045704 | Proteins for the Treatment of Epithelial Barrier Function Disorders | October 2020 | July 2022 | Allow | 21 | 1 | 1 | Yes | No |
| 17040471 | PRO-COAGULANT HISTONES | September 2020 | February 2022 | Abandon | 17 | 0 | 1 | No | No |
| 16982115 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE CHECKPOINT INHIBITOR THERAPY | September 2020 | September 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16982114 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DAMAGE ASSOCIATED WITH NSAID THERAPY | September 2020 | January 2023 | Abandon | 28 | 2 | 0 | No | No |
| 17002053 | MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE | August 2020 | May 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16992751 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY | August 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16986790 | AMYLIN ANALOGUES | August 2020 | August 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16925456 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | July 2020 | June 2021 | Abandon | 11 | 1 | 0 | No | No |
| 16924678 | ENDOMORPHIN-2, TETRAPEPTIDE DERIVATIVES THEREOF, AND USES THEREOF | July 2020 | February 2022 | Abandon | 19 | 2 | 0 | Yes | No |
| 16769732 | MODULATORS OF COMPLEMENT ACTIVITY | June 2020 | September 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16769015 | Incretin Analogs and Uses Thereof | June 2020 | April 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16763732 | PACAP STABILIZED PEPTIDE | May 2020 | February 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 16850818 | Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases | April 2020 | February 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16805370 | NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | February 2020 | August 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16638816 | IMMUNOTHERAPY AGAINST TRANSFERRIN RECEPTOR 1 (TFR1)-TROPIC ARENAVIRUSES | February 2020 | September 2024 | Abandon | 55 | 3 | 1 | Yes | No |
| 16750742 | PEPTIDE THERAPIES FOR REDUCTION OF MACULAR THICKENING | January 2020 | January 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16632546 | ULTRASOUND-ASSISTED SIMULATED DIGESTION METHOD OF MILK PROTEIN ACTIVE PEPTIDE AND APPLICATION THEREOF IN HEALTH FOODS | January 2020 | September 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16738792 | BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE | January 2020 | January 2022 | Abandon | 25 | 2 | 0 | No | No |
| 16628594 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | January 2020 | August 2023 | Allow | 44 | 0 | 0 | Yes | No |
| 16732545 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY | January 2020 | October 2022 | Abandon | 34 | 1 | 0 | No | No |
| 16725319 | METHOD OF TREATING LOW BLOOD PRESSURE | December 2019 | December 2023 | Abandon | 48 | 2 | 1 | Yes | No |
| 16712383 | CATIONIC ANTIMICROBIAL PEPTIDES | December 2019 | April 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16668754 | PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOF | October 2019 | August 2023 | Abandon | 46 | 3 | 0 | Yes | No |
| 16606455 | METHODS OF TREATING GASTROINTESTINAL MOTILITY-RELATED DISORDERS USING VARIANTS AND FUSIONS OF FGF19/FGF21 POLYPEPTIDES | October 2019 | August 2022 | Abandon | 34 | 0 | 1 | No | No |
| 16657507 | MEDICAMENT FOR MITIGATING CONDITIONS AND/OR SUPPRESSING ONSET OF PERIPHERAL NEUROPATHY INDUCED BY ANTI-MALIGNANT TUMOR AGENT | October 2019 | May 2022 | Allow | 31 | 3 | 0 | Yes | No |
| 16566992 | GLUCAGON ANALOGUES | September 2019 | June 2023 | Allow | 45 | 1 | 1 | Yes | No |
| 16485190 | GLP-1R AGONISTS AND USES THEREOF | August 2019 | February 2023 | Allow | 42 | 3 | 0 | Yes | No |
| 16480142 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | July 2019 | October 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16449632 | MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE | June 2019 | May 2020 | Allow | 11 | 1 | 0 | No | No |
| 16448910 | PEPTIDE-OLIGOUREA CHIMERIC COMPOUNDS AND METHODS OF THEIR USE | June 2019 | March 2022 | Abandon | 33 | 2 | 0 | No | No |
| 16435350 | Engineered Cyclic Peptides | June 2019 | November 2023 | Abandon | 53 | 5 | 1 | Yes | No |
| 16466488 | COMPOSITION FOR SUPPRESSING MUSCULAR ATROPHY | June 2019 | February 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16427493 | POLYPEPTIDES FOR USE IN SELF-ASSEMBLING PROTEIN NANOSTRUCTURES | May 2019 | July 2022 | Allow | 38 | 2 | 0 | Yes | No |
| 16465524 | FUNCTIONALIZATION OF BIOPOLYMERS WITH GROWTH FACTOR-BINDING PEPTIDES | May 2019 | December 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16348540 | NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | May 2019 | November 2021 | Allow | 30 | 1 | 0 | Yes | No |
| 16402612 | Tricalcium Phosphate Binding Peptides And Uses Thereof | May 2019 | December 2022 | Abandon | 44 | 2 | 1 | No | No |
| 16389292 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | April 2019 | July 2023 | Allow | 51 | 2 | 1 | Yes | No |
| 16340657 | METHODS AND COMPOSITION FOR DETECTING CAPN5 | April 2019 | January 2024 | Allow | 57 | 2 | 1 | Yes | No |
| 16372692 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | April 2019 | February 2022 | Allow | 34 | 3 | 1 | Yes | No |
| 16337886 | Methods And Compositions For Noninvasive Detection Of Organ Transplant Rejection | March 2019 | October 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16363890 | SAP AND PEPTIDOMIMETIC COMPOSITIONS FOR REDUCING SYMPTOMS OF INFLAMMATION | March 2019 | December 2022 | Abandon | 45 | 2 | 1 | No | No |
| 16288374 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | February 2019 | September 2020 | Abandon | 18 | 2 | 0 | No | No |
| 16324844 | SILK-DERIVED PROTEIN FOR TREATING INFLAMMATION | February 2019 | September 2021 | Allow | 31 | 2 | 1 | Yes | No |
| 16322214 | GLUTAMINE FOR PRESERVING, IMPROVING OR RESTORING KIDNEY FUNCTION | January 2019 | March 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16315388 | STABLE LIQUID FIBRINOGEN | January 2019 | August 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16256752 | INHIBITING TUMOR CELL MIGRATION BY INHIBITION OF KINESIN LIGHT CHAIN 1, VARIANT 1 (KLC1C) | January 2019 | December 2021 | Allow | 34 | 1 | 1 | Yes | No |
| 16313192 | ENDOMORPHIN-2, TETRAPEPTIDE DERIVATIVES THEREOF, AND USES THEREOF | December 2018 | August 2020 | Abandon | 20 | 2 | 1 | No | No |
| 16312357 | Modified Fibroin | December 2018 | November 2023 | Abandon | 59 | 3 | 1 | Yes | No |
| 16218990 | TARGETING WITH FIRBRONECTIN TYPE III LIKE DOMAIN MOLECULES | December 2018 | January 2023 | Abandon | 49 | 4 | 1 | Yes | No |
| 16216744 | PEPTIDE PARTICLE FORMULATION | December 2018 | December 2020 | Abandon | 24 | 2 | 0 | No | No |
| 16302846 | GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATES | November 2018 | February 2021 | Abandon | 27 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FISCHER, JOSEPH.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FISCHER, JOSEPH works in Art Unit 1658 and has examined 176 patent applications in our dataset. With an allowance rate of 40.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner FISCHER, JOSEPH's allowance rate of 40.3% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FISCHER, JOSEPH receive 2.27 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FISCHER, JOSEPH is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +51.7% benefit to allowance rate for applications examined by FISCHER, JOSEPH. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.0% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 10.5% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 28.6% of appeals filed. This is in the 3% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 95.5% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.